Literature DB >> 33535607

Combination of Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System (ODDS) for Cyclosporine-A.

Eleonora Terreni1, Erica Zucchetti1, Silvia Tampucci1,2, Susi Burgalassi1,2, Daniela Monti1,2, Patrizia Chetoni1,2.   

Abstract

A combination of in situ gelling systems and a loaded drug self-assembling nanomicellar carrier was chosen in this study as a new potential Ocular Drug Delivery System (ODDS) for Cyclosporine-A (CyA), a poorly water-soluble drug. Two non-ionic surfactants (d-α-tocopherol polyethylene glycol succinate, VitE-TPGS and polyoxyl 40 hydrogenated castor oil, RH-40) were used to produce the nanomicelles. The physical-chemical characterization of the nanomicelles in terms of CyA entrapment (EE%) and loading efficiency (LE%), cloud point (CP), regeneration time (RT), size and polydispersity index (PI) allowed us to select the best combination of surfactant mixture, which showed appropriate stability, high CyA-EE (99.07%), very small and homogeneous dimensions and favored the solubilization of an amount of CyA (0.144% w/w) comparable to that contained in marketed emulsion Ikervis®. The selected nanomicellar formulation incorporated into optimized ion-sensitive polymeric dispersions of gellan gum (GG-LA: 0.10, 0.15 and 0.20% w/w) able to trigger the sol-gel transition after instillation was characterized from technological (osmolality, pH, gelling capacity, rheological behavior, wettability, TEM and storage stability at 4 and 20 °C) and biopharmaceutical points of view. This new combined approach allowed us to obtain clear aqueous dispersions that were easy to instill and able to form a viscous gel when in contact with the tear fluid, improving CyA ocular bioavailability. Furthermore, this new ODDS prevented CyA transcorneal permeation, exhibited low cytotoxicity and prolonged the CyA resident time in the precorneal area compared to Ikervis®.

Entities:  

Keywords:  Cyclosporine-A; in situ gelling polymer; nanomicelles; ocular; pharmacokinetics in rabbits

Year:  2021        PMID: 33535607      PMCID: PMC7912864          DOI: 10.3390/pharmaceutics13020192

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  49 in total

1.  Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.

Authors:  Barbara Stella; Silvia Arpicco; Flavio Rocco; Susi Burgalassi; Nadia Nicosia; Silvia Tampucci; Patrizia Chetoni; Luigi Cattel
Journal:  Eur J Pharm Biopharm       Date:  2011-10-08       Impact factor: 5.571

Review 2.  Thermosensitive sol-gel reversible hydrogels.

Authors:  Byeongmoon Jeong; Sung Wan Kim; You Han Bae
Journal:  Adv Drug Deliv Rev       Date:  2002-01-17       Impact factor: 15.470

3.  In vitro evaluation of some parameters involved in mucoadhesion of aqueous polymeric dispersions.

Authors:  Susi Burgalassi; Daniela Monti; Silvia Tampucci; Patrizia Chetoni
Journal:  Pharm Dev Technol       Date:  2014-07-25       Impact factor: 3.133

4.  Chitosan nanoparticles for ocular delivery of cyclosporine A.

Authors:  Ebru Başaran; Evrim Yenilmez; Murat Sami Berkman; Gülay Büyükköroğlu; Yasemin Yazan
Journal:  J Microencapsul       Date:  2013-07-08       Impact factor: 3.142

5.  Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility.

Authors:  Aswani Dutt Vadlapudi; Kishore Cholkar; Ramya Krishna Vadlapatla; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-05       Impact factor: 2.671

6.  Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery.

Authors:  Ebru Başaran; Müzeyyen Demirel; Başar Sirmagül; Yasemin Yazan
Journal:  J Microencapsul       Date:  2010       Impact factor: 3.142

7.  Cyclosporine Amicellar delivery system for dry eyes.

Authors:  Han Kang; Kwang-Ho Cha; Wonkyung Cho; Junsung Park; Hee Jun Park; Bo Kyung Sun; Sang-Min Hyun; Sung-Joo Hwang
Journal:  Int J Nanomedicine       Date:  2016-06-21

8.  Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment.

Authors:  Silvia Tampucci; Daniela Monti; Susi Burgalassi; Eleonora Terreni; Erica Zucchetti; Filippo Baldacci; Patrizia Chetoni
Journal:  Pharmaceutics       Date:  2018-08-25       Impact factor: 6.321

9.  Formulation of Nanomicelles to Improve the Solubility and the Oral Absorption of Silymarin.

Authors:  Vieri Piazzini; Mario D'Ambrosio; Cristina Luceri; Lorenzo Cinci; Elisa Landucci; Anna Rita Bilia; Maria Camilla Bergonzi
Journal:  Molecules       Date:  2019-04-30       Impact factor: 4.411

Review 10.  Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents.

Authors:  Eliana B Souto; João Dias-Ferreira; Ana López-Machado; Miren Ettcheto; Amanda Cano; Antonio Camins Espuny; Marta Espina; Maria Luisa Garcia; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2019-09-06       Impact factor: 6.321

View more
  1 in total

Review 1.  Recent Developments in Ion-Sensitive Systems for Pharmaceutical Applications.

Authors:  Michał Rudko; Tomasz Urbaniak; Witold Musiał
Journal:  Polymers (Basel)       Date:  2021-05-18       Impact factor: 4.329

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.